Replimune Presented RP1 Data From The IGNYTE Anti-PD1 Failed Melanoma Cohort And RP2 Data In Uveal Melanoma At ASCO
Portfolio Pulse from Charles Gross
Replimune Group presented updated data from the IGNYTE clinical trial's anti-PD1 failed melanoma cohort and the ongoing Phase 1 trial of RP2 combined with nivolumab in uveal melanoma patients at the ASCO annual meeting.
June 03, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Replimune Group's updated data from the IGNYTE clinical trial and ongoing Phase 1 trial of RP2 may positively impact the company's stock price.
The updated data from the IGNYTE clinical trial and ongoing Phase 1 trial of RP2 presented at the ASCO annual meeting may be seen as a positive development for Replimune Group. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100